CoChat

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Published version of a preprint

The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.

Abstract

Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks. Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clinical activities. Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacology while analyses in untransformed cells illuminates significant differences. To resolve this apparent disconnect, drug behaviors are described at the molecular level. Nonkinase binding studies and kinome interaction analysis (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacology, may contribute for abemaciclib, and confounds AG-024322 analysis. CDK2 and CDK6 cocrystal structures with the drugs identify the molecular interactions responsible for potency and kinase selectivity. Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome. Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket. Integrating clinical drug exposures into the analysis predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9). Understanding the molecular components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs. Mol Cancer Ther; 15(10); 2273–81. ©2016 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0300

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Research works printed but not linked: 2

  1. Vidula, 2016, Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data, Clin Breast Cancer, 16, 8, 10.1016/j.clbc.2015.07.005 · DOI
  2. Copeland, 2005, Evaluation of enzyme inhibitors in drug discovery

Cited by

See all 477

Metadata

Authors
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., Yu, X., Nagata, A., VanArsdale, T., & Murray, B. W.
Affiliations
Pfizer (United States) (US)
Corresponding author
Murray, Brion W.
Venue
Molecular Cancer Therapeutics
Published
2016-10-01
Volume
15
Issue
10
Pages
2273-2281
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2491062142
Cited by
444
References
53
Citations by year
2026: 35 · 2025: 59 · 2024: 59 · 2023: 58 · 2022: 48 · 2021: 52 · 2020: 42 · 2019: 39 · 2018: 27 · 2017: 25
FWCI
27.43
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
cyclin-dependent kinase inhibitors, CDK4/6 inhibitors, drug selectivity, kinase specificity, dinaciclib, palbociclib, ribociclib, abemaciclib, CDK2, CDK6, ATP binding site, kinase redundancy, anticancer drug development
MeSH terms
Animals, Antineoplastic Agents, Cell Survival, Drug Interactions, Epithelial Cells, Humans, Leukocytes, Mononuclear, Models, Molecular, Molecular Conformation, Phosphorylation, Protein Binding, Cluster Analysis, Cyclin-Dependent Kinases, Drug Resistance, Neoplasm, Myocytes, Cardiac, Cell Line, Tumor, Protein Kinase Inhibitors, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0300
The paper
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., Yu, X., Nagata, A., VanArsdale, T., & Murray, B. W. (2016). Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0300

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.